Latest Industry Insights

Stem cell therapy using iPSC technology on the surface of the eye could cure blindness by replacing damaged corneal cells – a new hope for vision restoration.

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances in lipid nanoparticles and protein barcoding are enabling more precise, scalable, tissue-specific delivery.

Joel Eichmann discusses the challenges of scaling adherent cell culture and the innovations helping to streamline the transition from discovery to GMP manufacturing.

Technology Networks spoke with Stefan Foser, vice president of global pharma at Bruker, to explore how they integrate instrumentation, software and consumables to support early-stage pharma innovation.

Dr. Tomek Czernuszewicz shares insights on the limitations of traditional delivery techniques and how Revvity is advancing in vivo imaging through AI-powered tools.

We spoke with the developers and manufacturers of the CRISPR gene therapy used to treat KJ Muldoon’s rare genetic condition, CPS1, about how the product was created in just six months.

In this interview, we explore the limitations of pDNA, the advantages of mcDNA and how NunaBio’s technology could unlock new possibilities for safer, more efficient gene therapy.

Today, single-cell technologies are not only dissecting genomic, transcriptomic and proteomic profiles but also enabling dynamic measurements of cellular functions. Bruker's new Beacon Discovery Platform could make this a reality for more labs.

David Curtin discusses how the integration of MALS detectors with Empower software enhances biopharmaceutical QC, aligns with evolving regulatory demands and supports the future of complex biologic product analysis.

Learn more about how AI is advancing the mRNA drug discovery pipeline and what we can expect to see in the future in this interview with Dr. Davide De Lucrezia.